Preclinical immunogenicity and protective efficacy of a SARS-CoV-2 RBD-based vaccine produced with the thermophilic filamentous fungal expression system Thermothelomyces heterothallica C1.

Autor:	Gonzalez-Hernandez M; Research Center for Emerging Infections and Zoonoses, University of Veterinary Medicine Hannover, Foundation, Hannover, Germany., Kaiser FK; Research Center for Emerging Infections and Zoonoses, University of Veterinary Medicine Hannover, Foundation, Hannover, Germany., Steffen I; Research Center for Emerging Infections and Zoonoses, University of Veterinary Medicine Hannover, Foundation, Hannover, Germany.; Institute for Biochemistry, University of Veterinary Medicine Hannover, Foundation, Hannover, Germany., Ciurkiewicz M; Department of Pathology, University of Veterinary Medicine Hannover, Foundation, Hannover, Germany., van Amerongen G; Viroclinics Xplore, Schaijk, Netherlands., Tchelet R; Dyadic International, Inc., Jupiter, FL, United States., Emalfarb M; Dyadic International, Inc., Jupiter, FL, United States., Saloheimo M; VTT Technical Research Centre of Finland Ltd., Espoo, Finland., Wiebe MG; VTT Technical Research Centre of Finland Ltd., Espoo, Finland., Vitikainen M; VTT Technical Research Centre of Finland Ltd., Espoo, Finland., Albulescu IC; Virology Section, Infectious Diseases and Immunology Division, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, Netherlands., Bosch BJ; Virology Section, Infectious Diseases and Immunology Division, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, Netherlands., Baumgärtner W; Department of Pathology, University of Veterinary Medicine Hannover, Foundation, Hannover, Germany., Haagmans BL; Department of Viroscience, Erasmus Medical Center, Rotterdam, Netherlands., Osterhaus ADME; Research Center for Emerging Infections and Zoonoses, University of Veterinary Medicine Hannover, Foundation, Hannover, Germany.
Jazyk:	angličtina
Zdroj:	Frontiers in immunology [Front Immunol] 2023 Jun 09; Vol. 14, pp. 1204834. Date of Electronic Publication: 2023 Jun 09 (Print Publication: 2023).
DOI:	10.3389/fimmu.2023.1204834
Abstrakt:	Introduction: The emergency use of vaccines has been the most efficient way to control the coronavirus disease 19 (COVID-19) pandemic. However, the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern has reduced the efficacy of currently used vaccines. The receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) protein is the main target for virus neutralizing (VN) antibodies. Methods: A SARS-CoV-2 RBD vaccine candidate was produced in the Thermothelomyces heterothallica (formerly, Myceliophthora thermophila) C1 protein expression system and coupled to a nanoparticle. Immunogenicity and efficacy of this vaccine candidate was tested using the Syrian golden hamster (Mesocricetus auratus) infection model. Results: One dose of 10-μg RBD vaccine based on SARS-CoV-2 Wuhan strain, coupled to a nanoparticle in combination with aluminum hydroxide as adjuvant, efficiently induced VN antibodies and reduced viral load and lung damage upon SARS-CoV-2 challenge infection. The VN antibodies neutralized SARS-CoV-2 variants of concern: D614G, Alpha, Beta, Gamma, and Delta. Discussion: Our results support the use of the Thermothelomyces heterothallica C1 protein expression system to produce recombinant vaccines against SARS-CoV-2 and other virus infections to help overcome limitations associated with the use of mammalian expression system. Competing Interests: Author GA was employed by company Viroclinics Xplore. Authors RT and ME work for the company Dyadic International, Inc., and may use the vaccine for commercial use. Authors B-JB and BH filed a patent application on coronavirus nanoparticle vaccines. Authors MS, MW, and MV work for the company VTT Technical Research Centre of Finland, Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Gonzalez-Hernandez, Kaiser, Steffen, Ciurkiewicz, van Amerongen, Tchelet, Emalfarb, Saloheimo, Wiebe, Vitikainen, Albulescu, Bosch, Baumgärtner, Haagmans and Osterhaus.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu